ARCHIVES

FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.

This article is from The Cancer Letter archive.

Vol. 26 No. 13 | March 31, 2000

Download PDF Visit The Full Archive

Related Articles

European regulators plan more rigorous rules for accelerated approval in cancer.

November 11, 2005

NCAB Supports NCI Director’s Call For Increase In Management Funds.

December 8, 2000

Funding Opportunities

December 13, 2002

NCI Separates Carcinogenesis Research Efforts

February 18, 1977

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

June 11, 2014

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012